Loading…
Japanese maker of OTC pharmaceuticals and niche consumer health products, known for inventive small-category items.
Japanese maker of OTC pharmaceuticals and niche consumer health products, known for inventive small-category items.
Earns by creating a household or health product for a niche no one has served, backing it with heavy advertising, and selling it through drugstores and supermarkets; repeat purchases then carry the brand. Sawaday air fresheners and Netsusama fever-cooling sheets are examples sold on the same shelves as its medicines.
In one line: A niche OTC/consumer-health innovator.
Moat: narrow (brand, IP / patents). Track record of creating and branding new niche product categories ahead of competitors.
Headquarters: Osaka, Japan · Founded: 1886 · Employees: 3,731
Size Kobayashi Pharmaceutical (4967.T) is a Japan Consumer Staples company (Household/Personal Care) with a market value of $3.29B, the 336th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥6,991 on 6 Nov 2026.
Performance Over six months the shares gained 20.5%, against +2.6% for the median peer and +1.8% for the Japan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 3.7% over the last twelve months (peer median +3.7%); the operating margin is 6.2% (peer median 12.4%).
Valuation It trades at 50.2× forward earnings against a peer median of 16.7× (most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points below its cost of capital (5.0% WACC).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥167B | ¥166B | ¥166B | ¥173B | ¥166B |
| Revenue growth | — | 0% | -5% | +4% | — |
| Gross profit | ¥83.5B | ¥79.4B | ¥82.8B | ¥93.2B | ¥89.7B |
| EBITDA | ¥19.6B | ¥23.6B | ¥32.9B | ¥31.8B | ¥31.9B |
| Net income | ¥1.63B | ¥3.66B | ¥10.1B | ¥20.3B | ¥20.0B |
| Free cash flow | n/a | ¥12.3B | -¥14.8B | ¥5.60B | ¥17.2B |
| Capital expenditure | n/a | ¥14.0B | ¥26.6B | ¥13.6B | ¥16.2B |
| Total debt | ¥723M | ¥678M | ¥846M | ¥987M | ¥792M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Kobayashi Pharmaceutical 4967.T | $3.29B | +20% | +4% | 6% | 50.2× | 17.6% |
| Rohto Pharmaceutical 4527.T | $3.97B | +17% | +10% | 12% | 16.7× | -2.1% |
| Earth 4985.T | $682M | +6% | +6% | 4% | 17.7× | -2.5% |
| Lion 4912.T | $3.19B | +21% | +6% | 8% | 19.9× | -2.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4967.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.5% | +2.8% | 9th lowest of 21 |
| 6-month return | +20.5% | +2.6% | 7th highest of 21 |
| Distance from 52-week high | -5.4% | -23.5% | 5th highest of 21 |
| Revenue growth (TTM) | +3.7% | +3.7% | 11th highest of 21 |
| Operating margin | 6.2% | 12.4% | 4th lowest of 21 |
| Forward P/E | 50.2× | 16.7× | most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 17.6% | -0.2% | 2nd most demanding of 18 |
| Growth delivered (Del g) | +1.9% | +7.4% | 5th lowest of 18 |
| Hurdle (Req g minus delivered) | +15.7 pp | -3.7 pp | 2nd most demanding of 18 |
| ROIC minus cost of capital | -0.3 pp | +5.5 pp | 4th lowest of 20 |
| EV / EBITDA | 23.5× | 11.1× | 2nd most expensive of 17 |
| Net debt / EBITDA | -2.9× | -0.5× | 2nd least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kobayashi Pharmaceutical 4967.T | Japan | $3.29B | +20% | +4% | 6% | 50.2× | 17.6% | +1.9% |
| Hengan Int'l 1044.HK | Hong Kong | $3.28B | -16% | +2% | 11% | 9.1× | -8.8% | -0.1% |
| Lion 4912.T | Japan | $3.19B | +21% | +6% | 8% | 19.9× | -2.4% | +3.5% |
| Coty COTY | United States | $3.57B | +64% | -1% | 5% | 13.3× | 11.3% | +4.6% |
| Proya Cosmetics 603605.SS | China | $2.97B | -19% | +2% | 13% | 11.1× | -4.8% | +23.1% |
| Interparfums ITP.PA | France | $3.65B | +72% | -4% | 18% | 27.5× | 15.9% | +19.6% |
| Giant Biogene 2367.HK | Hong Kong | $2.76B | -34% | -10% | 32% | 9.7× | -8.0% | +34.9% |
| Rohto Pharmaceutical 4527.T | Japan | $3.97B | +17% | +10% | 12% | 16.7× | -2.1% | +13.7% |
| Winner Medical 300888.SZ | China | $2.69B | -2% | +4% | 11% | 20.9× | -4.3% | -2.6% |
| Gillette India GILLETTE.NS | India | $2.56B | -7% | +8% | 28% | 33.0× | 16.0% | +13.0% |
| LG H&h 051900.KS | South Korea | $2.56B | -8% | -3% | 3% | 18.5× | -0.1% | -4.1% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.40B | -29% | -2% | 24% | 27.3× | 15.4% | +7.4% |
| Colgate-Palmolive (India) COLPAL.NS | India | $4.83B | -23% | +9% | 28% | 32.2× | 30.8% | +4.5% |
| Cupid CUPID.NS | India | $4.83B | +158% | +122% | 34% | n/a | n/a | n/a |
| Softcare 2698.HK | Hong Kong | $2.20B | -5% | +25% | 25% | 14.4× | 8.7% | +20.9% |
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.92B | -28% | +32% | 31% | 15.0× | 4.7% | +41.1% |
| KOSE 4922.T | Japan | $2.16B | +7% | +3% | 4% | 27.2× | n/a | n/a |
| Reynolds Consumer Products REYN | United States | $5.08B | +10% | +2% | 14% | 14.6× | -0.2% | +2.7% |
| Cosmax 192820.KS | South Korea | $2.13B | +21% | +16% | 8% | 16.6× | n/a | n/a |
| Pola Orbis 4927.T | Japan | $1.96B | +8% | +1% | 10% | 28.8× | -3.1% | -0.7% |
| Kolmar Korea 161890.KS | South Korea | $1.89B | +23% | +13% | 10% | 13.0× | -0.9% | +15.5% |